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The success of theWorld Health Organization recommended “Expanded Program of Immu-
nization” (EPI) and similar regional or national programs has been astounding. However,
infectious threats currently not covered by these programs continue to infect millions of
infants around the world. Furthermore, many infants do not receive existing vaccines either
on time or for the required number of doses to provide optimal protection. Nor do all
infants around the world develop the same protective immune response to the same
vaccine. As a result approximately three million infants die every year from vaccine pre-
ventable infections. To tackle these issues, new vaccines need to be developed as well
as existing ones made easier to administer. This requires identification of age-optimized
vaccine schedules and formulations. In order to be most effective this approach will need
to take population-based differences in response to vaccines and adjuvants into account.
This review summarizes what is currently known about differences between populations
around the world in the innate immune response to existing as well as new and promising
vaccine adjuvants.
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INTRODUCTION
Around the world the Expanded Program of Immunization (EPI)
is responsible for immunizing infants<12 months of age against a
number of infectious threats including polio, diphtheria, tetanus,
pertussis, invasive Haemophilus influenzae type b (Hib), hepatitis
B, and tuberculosis (TB), with the more recent addition of pneu-
mococcus, measles, rubella, and rotavirus (Clements, 2003; Levine,
2011). Without doubt, current EPI vaccines played an enormous
role in diminishing mortality and morbidity from these infec-
tious diseases in early life (Levine and Robins-Browne, 2009).
National and regional programs focused on complementing the
World Health Organization (WHO) recommended list of vaccines
(WHO, 2012), such as rubella [as part of the measles, mumps,
rubella (MMR) combination vaccine] or the seasonal influenza
virus vaccines, further contributed to reduction of infections in
infants (Kennedy and Poland, 2011). Together, these vaccination
programs represent major triumphs of preventive medicine and
public health (Clemens et al., 2010; Levine, 2011). But while
vaccines represent the most cost-effective life-saving medical inter-
vention in history (Centers for Disease Control and Prevention,
1999; D’Argenio and Wilson, 2010; Pulendran and Ahmed, 2011),
∼three million children still die every year of infectious diseases
that are preventable with presently available vaccines (Clemens
et al., 2010).
Whereas vaccine effectiveness takes into account programatic
variables such as vaccine coverage and cold-chain/delivery failures,
vaccine efficacy is the measure of the impact of immunization
under well-controlled study conditions (Gartlehner et al., 2006).
Vaccine efficacy is usually assessed in studies that lead to vac-
cine licensure, where trials are conducted in defined populations
(Gartlehner et al., 2006). Failure of vaccine effectiveness to avoid
the∼three million annual vaccine preventable deaths may be due
to suboptimal vaccine coverage and breaks in the cold-chain of
vaccine storage and delivery, but may also be due to failure of
vaccine efficacy in populations different from the ones studied in
the original trials (Labeaud et al., 2009). Vaccine formulations and
schedules are similar in most countries, assuming that response
to vaccination would be similar in children living in different
regions of the world (Clements, 2003; Arevshatian et al., 2007;
Poland et al., 2008). But several vaccines are known to perform
less well in developing country populations than in populations
residing in the industrialized world (Clemens and Jodar, 2005a).
This has been hypothesized to be secondary to variation in envi-
ronmental exposures (Labeaud et al., 2009). Yet, even within the
“same” environment of a given population differences in vaccine
responses have been identified (Poland et al., 2008; Ovsyannikova
and Poland, 2011), suggesting the factors that lead to variation in
vaccine efficacy are likely complex.
Immune responses to vaccines are known to be influenced by a
number of parameters, including age, gender, race, the quality and
quantity of vaccine antigen(s), the number of doses administered,
and the route of immunization (Poland et al., 2008; Siegrist and
Aspinall, 2009; Smolen et al., 2012). However, in the EPI and most
national programs, similar vaccines are given via the same route,
mostly at approximately the same age for the same number of
doses (Clements, 2003; Levine, 2011); route, age of recipient, and
number of doses are therefore unlikely culprits for variation in
vaccine efficacy in different populations. The reasons underlying
variation in vaccine efficacy in different populations must then
reside somewhere on the axis of host-environment interactions
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that differ between populations. Building on the observations of
differences in efficacy of some of the global EPI and national vac-
cine programs and the central importance of adjuvant responses
for a protective vaccine response, this review will highlight the pos-
sible role of variation between populations in response to vaccine
adjuvants in the overall variation of vaccine efficacy.
DIFFERENCES ACROSS THE GLOBE IN THE IMMUNE
RESPONSE TO VACCINATION
Bacille Calmette–Guerin (BCG), a live attenuated strain of
Mycobacterium bovis, is currently the only licensed vaccine avail-
able against TB and has been part of the EPI since 1974 (Clements,
2003). Most countries participating in the EPI give BCG at, or
soon after birth (Lalor et al., 2009). In infants, past BCG vacci-
nation trials showed consistently high efficacy against the severe
forms of systemic childhood TB (miliary TB or TB meningitis)
(Rodrigues et al., 1993; Trunz et al., 2006). However, BCG is also
the first and most studied example exhibiting geographical differ-
ences in response to vaccination: efficacy of BCG in the prevention
of pulmonary TB ranges between 0 and 80%; nearly half of this
variability can be explained by geographical differences between
study sites, more specifically by differences in latitude (Fine, 1995).
For example, clinical trials show good protection against adult pul-
monary TB in the UK, but little protection in Malawi (Lalor et al.,
2009).
Although none of the infant BCG vaccine trials were conducted
in Africa where TB is rampant, it is thought that BCG vaccination
offers similar protection to infants in all settings (Rodrigues et al.,
1993; Trunz et al., 2006). However, striking population differences
in the adaptive immune responses to BCG vaccination between
for example the UK vs. Malawian or Gambian infants suggest
the possibility that BCG vaccination might in fact not offer equal
protection to infants in different countries (Lalor et al., 2011).
Malawian and Gambian infants develop T cells with a cytokine
profile following BCG that is very different from that developing
in UK infants, who show strong antigen-specific INFγ dominated
T helper 1 (Th1) responses (Lalor et al., 2011). And a BCG study
in Indonesia identified not only INFγ but marked induction of IL-
5 and IL-13 in BCG-vaccinated infants, which contrasts with the
findings in Gambian, Malawian, as well as South African, and UK
infants (Djuardi et al., 2010). The impact of variation in timing of
BCG vaccination provides further evidence of regional differences
even within a single continent. A delay in administering BCG from
birth to 2–4 months of age can result in greater immunogenic-
ity (South Africa) (Kagina et al., 2010), reduced immunogenicity
(Gambia) (Burl et al., 2010), or no difference (Malawi) (Dock-
rell et al., 2012). Overall, this suggests that even at such young
age infants from different regions have different immunological
set-points and respond differently to BCG vaccination. While we
do not know what constitutes a protective vaccine response [e.g.,
in South African infants the numbers of T cells making IFNγ,
TNFα, and interleukin 2 (IL-2) do not correlate with protection
against diseases (Kagina et al., 2010; Soares et al., 2008; Abebe,
2012; Tameris et al., 2013)], the different cytokine biosignatures
following infant BCG vaccination in different settings could also
indicate variability in the protective efficacy of infant BCG vac-
cination (Lalor et al., 2009; Dockrell et al., 2012). While genetic
differences between populations may play a role in the variable
response to BCG, the differences in immune responses to BCG
vaccination between populations have mainly been shown to be
due to environmental variation (Packe and Innes, 1988; Rodrigues
et al., 1993; Fine, 1995), including prior exposure to environmen-
tal mycobacteria (Fine, 1995). Furthermore, particular prenatal
(mother’s body mass index) and perinatal (season of birth) envi-
ronments are known to have a lasting effect on the adaptive
immune response of infants to BCG vaccination (Miles et al., 2008;
Lalor et al., 2009). Thus differences in environmental exposure
strongly contribute to variation in BCG efficacy.
Lower latitude does not always lead to lower response to infant
vaccination. This is evidenced by the immune response to Hib con-
jugate vaccines. Immunization of infants with three doses of the
polyribose-ribitol-phosphate (PRP) polysaccharide-protein con-
jugate vaccines has had a remarkable impact in bringing invasive
Hib disease to the verge of elimination in most industrialized and
many developing countries (Lagos et al., 1998a,b; Clemens and
Jodar, 2005b; Sow et al., 2009). Population-based differences in
response to Hib vaccination emerged early in the development of
Hib vaccines. A vaccine consisting of PRP coupled to diphthe-
ria toxoid (PRP-D) was initially licensed following a randomized
controlled trial showing high efficacy in Finnish children (Eskola
et al., 1990; Griffiths et al., 2012). However, PRP-D proved inef-
fective in preventing Hib carriage and disease in Alaskan Native
infants (Siber et al., 1990; Ward et al., 1990; Mohle-Boetani et al.,
1993; Galil et al., 1999; Lee et al., 2006; Singleton et al., 2006;
Asturias et al., 2009). On the other hand, antibody responses (to
a Hib-Tetanus conjugate) were found to be higher among Native
South American Indian infants compared to infants in the USA,
Europe, or Israel (Castillo de Febres et al., 1994; Levine et al., 1997;
Hoppenbrouwers et al., 1998; Asturias et al., 2009). Investigations
into possible reasons for this superior Hib vaccine response in
South American Native Indians revealed an association of higher
vaccine antibody titers with an increased number of household
members (Levine et al., 1997). This association led to the sugges-
tion that infants living in crowded conditions might be exposed
more frequently to Hib-cross-reacting bacteria as compared to
infants living in less crowded environments. The finding that
infants with superior anticapsular Hib antibody responses also
have higher antibody responses to tetanus toxoid (the carrier pro-
tein in Hib-T) but not to diphtheria toxoid (given as a vaccine)
indicates that superior responders to Hib are not simply over-
all immunologically superior vaccine responders. When Lee et al.
(2006) examined the serum anti-PRP antibody concentration of
monozygotic (MZ) and dizygotic (DZ) twin pairs in the Gambia,
genetic based heritability in antibody responses to Hib conjugate
vaccine was estimated to be 51%, indicating a significant genetic
contribution to variation in the response. Furthermore, siblings
of patients with H. influenzae meningitis have impaired responses
to Hib vaccine (Granoff et al., 1983), lending further support to
a host genetic component responsible for differential responses to
Hib vaccination. It thus appears that population-based differences
in Hib vaccine responses could be affected by differences between
populations in both, host genetic and environmental exposures.
In the EPI, the hepatitis B vaccine (HepB) is given in three
doses starting either at birth or with a delay to 6–8 weeks of life
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(Clements, 2003). For HepB, the overall response rates are high
irrespective of differences in timing of vaccination, but differences
between populations have been described. For example, while both
Ladino (mestizo Spanish descent) and Native Indian Guatemalan
infants develop high rates (96–100%) of protective antibodies after
receiving HepB, Native Guatemalan Indian infants develop signif-
icantly (p< 0.01) higher geometric mean anti-HBs (anti-hepatitis
B surface) antibody concentrations than Ladino infants (Asturias
et al., 2009). Malnourished infants in this study, irrespective of
racial background responded as strong as well-nourished infants
(Asturias et al., 2009). This suggests that differences in the anti-
body response to HepB between populations exist, but that these
do not reflect differences in nutritional status. A study in China
comparing persistence of Hep B titers following infant immuniza-
tion over time suggested that HepB infant vaccination was less
effective in socio-economically disadvantaged areas where HBV
infection remained hyperendemic, and that the long-term efficacy
and immunogenicity of infant HepB vaccination can be modified
by host as well as environmental factors (Wang et al., 2006). Some
of the host related (genetic) factors have been identified (Alper
et al., 1989); the precise environmental influences have yet to be
determined.
For other protein-based vaccines, such as tetanus, diphtheria,
and pertussis few studies have investigated differences in vaccine
response between populations. While initially only minor vari-
ation according to race or ethnicity had been observed in the
immune response of US children following tetanus (single anti-
gen) vaccination, antibody titers in Hispanic-American children
began to decline earlier than in non-Hispanic Americans (Ger-
gen et al., 1995). Furthermore, immune responses to all antigens
contained in the combined DTaP-Hib vaccine were shown to be
significantly lower in Belgian vs. Turkish infants (Hoppenbrouw-
ers et al., 1999). The factors associating with these differences have
not been investigated, but suggest that population-based differ-
ences in the response to tetanus, diphtheria, and pertussis may
exist as well.
The response to measles vaccine (MV) has been interrogated
in some depth with respect to differences between populations.
Immunogenicity was found to differ between US Caucasian and
African-American racial groups (Haralambieva et al., 2011b) and
reactogenicity (as measured by fever following administration of
MV) was higher in Amazon basin tribes (Black et al., 1971). Heri-
tability of>90% in the immune response to MV strongly suggests
that immune response differences between populations mostly
relate to differences in host genetics (Poland et al., 2007).
Differences in immune response to influenza vaccination have
most commonly been ascribed to the pre-existing influenza-
specific immunity, rather than differences in host genetics or envi-
ronmental exposures. However, a study in Gabon, Africa identified
lower antibody and cellular responses to influenza vaccination
in rural as compared to semi-urban influenza-naïve schoolchild-
ren, suggesting environment may play a part in variable influenza
vaccine responses (van Riet et al., 2007a). And since significant
interindividual variability exists in influenza vaccine responses
even for individuals living in the same environment, a host genet-
ics appears to contribute to variable influenza vaccine responses
as well (Bucasas et al., 2011).
Lastly, ample evidence documents that the responses to oral
vaccines (polio, rotavirus, cholera, salmonella, and shigella) can
vary significantly between regions of the world (reviewed in
Levine, 2010). For oral vaccines, these differences have been
ascribed to the existence of an “intestinal barrier” to successful
oral immunization of people in less developed countries (Levine,
2010). While more readily conceptualized (variation in environ-
mental exposure may lead to variation in intestinal microbiota that
may affect vaccine “take”), even for oral vaccines, precise cause-
effect mechanisms leading to lower vaccine efficacy in resource-
poor vs. -rich regions of the world have not been identified.
Thus, despite many differences between populations in immune
responses to oral or parenteral vaccination, for most vaccines the
underlying mechanism/s that lead to differences in vaccine efficacy
are far from clear.
CENTRAL ROLE FOR INNATE IMMUNE ACTIVATING
ADJUVANTS IN THE IMMUNE RESPONSE TO VACCINATION
Several decades ago, Dr. C Janeway Jr. revealed what he called
the “dirty little secret” of immunology (Janeway, 1989): vac-
cines only work because of the “dirt” in them. This “dirt,” he
suspected, would consist of microbial products that function as
adjuvants, activating the immune system, and leading to a long-
lived protective response. In his quest to determine the nature
of these innate activating substances, Janeway discovered innate
immune activating receptors, of which Toll-like receptors (TLRs)
are now the best-known example. Dr. Janeway’s premise suggests
that, given their impressive success, innate activating substances
must also be present in the currently already licensed vaccines.
To date, the role of specifically TLRs for existing vaccines has
been unequivocally linked to outcome for only few human vac-
cines: (1) Subjects deficient in TLR 1/2 signaling fail to respond
to Lyme vaccination (Alexopoulou et al., 2002); (2) the ∼10% of
human recipients who fail the standard HepB vaccination respond
perfectly well if a TLR4 ligand is added (Jacques et al., 2002; Van-
depapelière et al., 2005); (3) TLR polymorphisms associate with
an altered immune response to BCG administered to infants at
birth (Randhawa et al., 2011). For most other licensed vaccines,
there is only indirect evidence implicating TLR function: Hib-
OMPC – TLR2 (Galdiero et al., 2004), meningococcal – TLR2
(Massari et al., 2002), pertussis – TLR4 (Higgins et al., 2003),
influenza – TLR7 (Lund et al., 2004), measles – TLR2/TLR4
(Bieback et al., 2002; Hahm et al., 2007). Nevertheless, the fun-
damental role for the innate immune system in sensing vaccines,
and in programing protective adaptive immune responses has
been increasingly recognized (Pulendran and Ahmed, 2011). More
specifically, it is now clear that it is the function of particular adju-
vants activating the innate immune system that determines the
magnitude and quality of adaptive immune response following
immunization (Pulendran and Ahmed, 2011). It follows that vari-
ation between populations in antibody or cell mediated adaptive
immune responses to vaccination may centrally involve variation
between populations in the innate immune response to particular
adjuvants.
Despite years of research, few adjuvants have been licensed for
use around the world (reviewed in Pulendran and Ahmed, 2011;
Hawken and Troy, 2012; Levy et al., 2012): alum (an aluminum
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salt-based adjuvant), AS04 (a combination adjuvant composed of
monophosphoryl lipid A (MPL, a TLR4 ligand) and alum) and
oil-in-water emulsions (such as MF59 and AS03). Since Janeway’s
discovery, we have learned much about the mechanisms of action
of each of these adjuvants (reviewed in Pulendran and Ahmed,
2011; Levy et al., 2012). Alum-based adjuvants via interactions
with cell- and lysosomal-membrane lipids trigger activation of
the NALP3 (NLR family, pyrin domain containing 3) inflamma-
some and lead to release of pro-inflammatory cytokines. However,
the precise mechanisms involved in the human in vivo response
to alum as an adjuvant are still unclear. Clear however is the fact
that alum enhances antibody as well as cell mediated responses
to (hepatitis B virus; human papillomavirus; diphtheria, pertussis,
and tetanus; Hib; pneumococcal conjugate) vaccination. Oil-in-
water emulsions such as MF59 and AS03 are licensed as adjuvants
for seasonal and pandemic influenza vaccination. They are mainly
composed of squalene, a cholesterol precursor and polysorbate
(reviewed in Levy et al., 2012). Such emulsions trigger local recruit-
ment of innate cells at the injection site and draining lymph
node and enhance subsequent induction of antibody responses.
MF59 adjuvanted vs. non-adjuvanted trivalent influenza vaccine
results in higher antibody titers maintained for prolonged peri-
ods of time and enhances affinity and cross-protection of the
vaccine in children against seasonal influenza virus strains (Khu-
rana et al., 2011; Pulendran and Ahmed, 2011). The oil-in-water
emulsion of AS03 has been licensed in Europe as adjuvant for vac-
cines against influenza (Pulendran and Ahmed, 2011). Saponins
such as QuilA or QS21 have potent immunostimulatory capacities,
potentiate antibody production, and induce both CD4 and CD8
T cell responses (reviewed in Levy et al., 2012). Similar to alum,
saponins activate the innate NALP3 inflammasome pathway and
are contained in the highly immunogenic RTS,S malaria vaccine.
An emerging class of adjuvants is one Janeway first identified: TLRs
(reviewed in Pulendran and Ahmed, 2011; Levy et al., 2012). The
neisserial outer membrane protein (OMP) complex has been used
as a vaccine adjuvant in Hib-OMP vaccines for some time; OMP is
a TLR2 agonist and directly activates the innate immune system.
The adjuvant AS04 consists of MPL, which is a lipopolysaccha-
ride derivative and a TLR4 ligand. AS04 is licensed for use, in
combination with alum, in GlaxoSmithKline’s Cervarix vaccine
against human papillomavirus and the vaccine against hepatitis
B virus. Adsorbed to alum, MPL enhances antibody responses in
comparison to alum alone.
DIFFERENCES BETWEEN POPULATIONS IN THE INNATE
IMMUNE RESPONSE TO ADJUVANTS
Since adjuvants function via activation of the innate immune
system, contrasting overall innate immune response between pop-
ulations to adjuvants would allow direct testing of the hypothesis
that differences in response to adjuvants between populations con-
tribute to differences in vaccine efficacy. Unfortunately, neither
the response to Alum, nor MF59, AS03, or to the saponins has
yet been contrasted between populations in a direct side-by-side
evaluation. Data exist however, for several TLR and other pattern-
recognition receptor (PRR) ligands, i.e., for Janeway’s originally
discovered adjuvants, many of which are under intense scrutiny as
novel vaccine adjuvants (Levy et al., 2012).
There is very strong evidence that innate immune response
to PRR-based adjuvants varies between children from different
regions and populations. For example, comparing TLR-mediated
innate immune responses in cord blood from Papua New Guinean
(PNG) vs. Australian (AUS) infants, van den Biggelaar et al.
(2009) found that cord blood mononuclear cells (CBMC) from
PNG newborns produced lower IL-6 and type-I IFN responses
to lipoteichoic acid (a TLR2 ligand), lower TNF-α responses to
lipopolysaccharide (LPS; a TLR4 ligand), but higher BCG-induced
IL-10 and IFN-γ responses. They also determined that the expres-
sion of TLR2 and TLR9 (mRNA) on resting CBMC was higher
but that of TLR4 lower in PNG as compared to AUS infants (van
den Biggelaar et al., 2009). Furthermore, AUS cord-derived naive
T cells showed an enhanced and more rapid proliferative response
in an autologous, antigen-presenting cell (APC)-dependent cul-
ture system as compared to PNG cord blood cells. This appears to
have been the result of differences in neonatal APC rather than T
cell function (Lisciandro et al., 2012b). In contrast, resting PNG
APCs exhibited higher baseline levels of activation and inhibitory
markers and were less responsive to stimulation in vitro. Based
on these data it was suggested that children born under mod-
ern environmental conditions (i.e., AUS) exhibit increased APC
reactivity at birth compared with children born under traditional
environmental conditions (i.e., PNG) (Lisciandro et al., 2012b).
The same group (Lisciandro et al., 2012a) next investigated the
ontogeny of the innate immune response to TLR and nucleotide-
binding oligomerization domain (NOD)-like receptor agonists
including alum in PNG infants over the first 2 years of life. Depend-
ing on the ligands and cytokines studied, different age-related
patterns were found: alum-induced IL-1β and CXCL8 responses
significantly declined with increasing age, inflammatory (IL-6,
IFNγ) responses to TLR2 and TLR3 agonists increased, while
IL-10 responses remained constant or increased during infancy.
Lisciandro’s et al. (2012a) data also suggest that innate immune
development may vary between diverse populations, as the pattern
of innate immune development they observed in PNG infants dif-
fered from that they had observed previously in AUS infants and
infants born and raised in the developed Western world. The devel-
opmental pattern of cytokine production after TLR stimulation
in infants in the Western world has been characterized in detail
(reviewed in Kollmann et al., 2012). For example, after TLR stim-
ulation of whole blood, production of anti-inflammatory innate
cytokines (IL-10) dominates in preterm infants, whereas produc-
tion of Th17 cell-promoting cytokines IL-6 and IL-23 dominates
in term infants. As a result term infants have elevated numbers and
increased function of Th17 cells as compared to adults. Production
of IL-10, IL-6, and IL-23 declines over the first few years of life;
this decline is paralleled by a steady increase in production of the
pro-inflammatory cytokines TNFα, IL-1β in whole blood, as well
as purified monocytes and conventional dendritic cells (cDCs).
TLR-induced antiviral and Th1 cell-supporting type 1 IFNs in
plasmacytoid dendritic cells (pDCs), production of which is sub-
stantially reduced at birth, rapidly reach adult-level production
within a few weeks after birth. One of the last cytokines to reach
adult-level production in cDCs after TLR stimulation is IL-12p70,
which is known to promote the development of Th1 cell immune
responses.
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This “developed nation” pattern contrasts with patterns that
have emerged from recent longitudinal cohort studies analyzing
human innate immune ontogeny over the first years of life in
resource-poor settings such as South Africa (Reikie et al., 2012),
The Gambia (Burl et al., 2011), and Ecuador (Teran et al., 2011).
In these studies, Th1-supporting and pro-inflammatory innate
cytokine production following TLR stimulation decreased (or
remained stably low) in infancy instead of increasing to adult
high levels. Of note, the same study that followed innate ontogeny
in South Africa (Reikie et al., 2012) also followed their subjects’
antibody response to EPI vaccination, and detected a surprisingly
low level of protective antibodies for most of the first year in
South African infants (Reikie et al., 2012). It thus appears as if
lower innate immune responses may correlate with lower vac-
cine antibody responses. However, developmental trajectories of
innate immune ontogeny likely will not simply follow a resource
rich vs. resource-poor pattern, but instead exhibit more com-
plexity due to interactions of variable host genetics and differing
environmental exposures. Supporting a complex nature of these
host-environment interactions in determining innate immune
ontogeny are several observations: non-allergic children born and
raised in Australia show progressive and significant age-related
increases in innate cytokine responses (IL-1β, IL-6, TNFα, and IL-
10) to virtually all TLR ligands (Tulic et al., 2011). In contrast,
allergic AUS children show exaggerated innate responses at birth
but a relative decrease with age thereafter (Tulic et al., 2011). Thus
allergic vs. non-allergic children from similar racial (genetic) and
socioeconomic background develop along opposing trajectories,
with the allergic children more akin to children born and raised in
resource-poor settings.
While this data strongly support the notion that different devel-
opmental trajectories of innate immune ontogeny exist for infants
from different populations, given the heterogeneity of innate
immune development within a given population (Randhawa et al.,
2011), and the many variables that can influence innate immune
analysis (Blimkie et al., 2011), this hypothesis will have to be tested
in a well-controlled, direct side-by-side comparison. Furthermore,
how such differences impact response to vaccination and protec-
tion from infection represents an exceptionally important issue to
address. We do however already know some of the genetic and
environmental factors that lead to alterations in innate immune
development, and by extrapolation, can attempt to connect these
variables with variation in vaccine immunogenicity or efficacy in
order to explore the underlying hypothesis that variation in innate
adjuvant response leads to variation in vaccine efficacy.
IMPACT OF GENETICS ON DIFFERENCES BETWEEN
POPULATIONS IN THE INNATE IMMUNE RESPONSE TO
ADJUVANTS
The immunogenetic basis for variation in immune response to
vaccines in humans remains largely unknown (Poland et al., 2008;
Kennedy and Poland, 2011). As described above, the Hib vaccine
response is known to vary between populations following the same
pattern as variation in host susceptibility to Hib disease (summa-
rized in Lee et al., 2006), suggesting that host genetic variation may
contribute to variation in Hib vaccine responses. It also has long
been known that functional mutations in innate immunity-related
genes vary between populations, possibly as a result of genetic
drift (de Craen et al., 2005; Greene et al., 2009) and/or differ-
ences in infectious pressure (Ferwerda et al., 2009; Fumagalli et al.,
2009; Greene et al., 2009; Boef et al., 2012). Genetic influences on
vaccine response are thus likely; this could certainly also include
genes relevant for innate immune responses to adjuvants (Poland
et al., 2007). Despite the fact that genetics clearly influences innate
immunity (Netea and van der Meer, 2011), the role of genetics
in the innate immune response to adjuvants early in life remains
unexamined.
Concrete roles of host genetic variation in innate immune
genes on vaccine responses have been assigned for only few vac-
cines. For example, TLR polymorphisms associate with an altered
immune response to BCG administered to infants at birth (Rand-
hawa et al., 2011). And heritability of the immune response to MV
contained in the MMR vaccines is almost 90%, while the heritabil-
ity for mumps and rubella contained in the same vaccine is only
39 and 46%, respectively (Haralambieva et al., 2011b; Kennedy
et al., 2012). These data clearly point out that the impact of genet-
ics on vaccine response is specific to each vaccine component.
With respect to MV, Dr. Poland and his group have shown that
polymorphisms in HLA, cytokine, cytokine receptor, and innate
immune response genes are all associated with variation in vac-
cine response (Kennedy et al., 2012). For example, variation in the
measles virus receptor CD46, innate PRR (DDX58, TLR2, 4, 5, 7,
and 8) and intracellular signaling intermediates (MAP3K7, NFK-
BIA), and key antiviral molecules (VISA, OAS2, MX1, PKR) as well
as cytokines (IFNA1, IL4, IL6, IL8, IL12B) and cytokine receptor
genes (IL2RB, IL6R, IL8RA) all feature in the genetic control of
both humoral and cellular immune responses to MV. In other
studies, innate immune genes have also been found to impact
the immune response to mumps, rubella, influenza, and smallpox
vaccination (Haralambieva et al., 2011a).
Evidence from genetic microsatellite analysis of African eth-
nic groups has identified unprecedented genetic diversity, reflect-
ing the long evolutionary history of humans residing in Africa
(Tishkoff et al., 2009). This also predicts that within Africa in par-
ticular, the many genotypes will likely produce many different
phenotypes, i.e., response to adjuvants (and with that to vac-
cination) can be expected to vary more widely in Africa than
elsewhere. This has already proven to be the case for the MMR
vaccine response (Dhiman et al., 2008). Furthermore, twin stud-
ies in The Gambia have identified important variation in genetic
determinants on the early phase of the infant vaccine responses
to HepB, oral polio, tetanus, and diphtheria vaccination (New-
port et al., 2004; Marchant et al., 2006). The relevant genes have
unfortunately not yet been identified.
ENVIRONMENTAL EXPOSURE DIFFERENCES BETWEEN
POPULATIONS AND VARIATION IN THE INNATE IMMUNE
RESPONSE TO ADJUVANTS
Because of its sentinel function, the innate immune system has to
be particularly sensitive to environmental stimuli (Graham et al.,
2006). Furthermore, the recently described concept of “trained
immunity,”i.e., memory-like innate immune function after micro-
bial encounters (Netea et al., 2011) suggests that environmental
exposure can be expected to be a major modulator of human
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innate immune adjuvant response that persists throughout infancy
and beyond (Kollmann et al., 2012). Mechanisms linking environ-
mental exposures during fetal and early life to vaccine responses
early as well as later in life possibly relate to alteration of the
epigenome (Djuardi et al., 2011; Hochberg et al., 2011; Netea et al.,
2011).
IMPACT OF PRENATAL ENVIRONMENT
Variation in exposure to environmental factors during pregnancy
is thought to impact not only the maternal but also the fetal
immune system (Djuardi et al., 2009). For example, maternal
exposure to farm animals during pregnancy was strongly asso-
ciated with up-regulation of innate immune receptors and a lower
degree of allergic sensitization in a child born to a farmer mother
(reviewed in Djuardi et al., 2011). Maternal exposure to micro-
bial compounds and consumption of farm dairy products was
also associated with increased T helper 1 (Th1)-type (IFN-γ)
and pro-inflammatory (TNF-α) cytokines in cord blood. Chronic
infections during pregnancy with helminths, Trypanosoma cruzi,
Plasmodium spp., and HIV all are known to affect the development
of fetal innate immunity and responses to vaccines (reviewed in
Dauby et al., 2012). For example, cells of neonates born to mothers
who had acquired P. falciparum infection 1 month before delivery
had significantly higher interferon-γ and tumor necrosis factor-α
responses after stimulation with the TLR ligands lipopolysaccha-
ride and polyinosine-polycytidylic acid, compared with cells of
neonates born either to mothers free of P. falciparum infection
or to mothers who were successfully treated for malaria during
pregnancy (Adegnika et al., 2008). How these prenatal environ-
mental variations impact postnatal vaccine responses has not been
studied. Furthermore, prenatal environmental stimuli have long-
lasting effects on postnatal development beyond vaccine responses
(Graham et al., 2006), a paradigm furthered in the “developmental
origin of health and disease” (Barker, 2007; Miles et al., 2008).
IMPACT OF PERINATAL ENVIRONMENT
Mode of birth, birth weight, and season of birth impact postnatal
innate immune ontogeny. The normal birth process stimulates an
acute phase reaction in the newborn infant (Marchini et al., 2000);
as a result innate cytokine production following TLR stimulation
of cord blood is significantly higher in cases of vaginal delivery
than in cases of elective (no labor) cesarean section (Malamitsi-
Puchner et al., 2005; Belderbos et al., 2011; Blimkie et al., 2011).
Season of birth impacts early life innate immune development
(Moore et al., 2001, 2006; Belderbos et al., 2011). Specifically, birth
in winter months is associated with lower TLR3 mediated IL-12p70
production and higher production of IL-10 upon stimulation of
TLR7; this has been observed to lead to lower vaccine responses
(Belderbos et al., 2011). Birth weight and season in fact predict
response to vaccination not just in childhood but into adulthood
(Moore et al., 2004).
IMPACT OF POSTNATAL ENVIRONMENT
Evaluation of the effect of urban vs. rural environment on TLR-
induced innate immune responses in infants in South America
was the first to reveal striking influence of postnatal environ-
ment on innate immunity, with IFNγ and IL-10 production both
significantly elevated in urban compared to rural infants (Teran
et al., 2011). In European infants, TLR responses differ already at
the age of 1 month according to environmental exposure during
the first month of life, with concentrations of monocytes neg-
atively associating with breastfeeding and siblings in the home,
and positively associating with exposure to pets (Belderbos et al.,
2011). The concept of “age-specific windows of vulnerability” to
external influences during early postnatal life that modulate long-
term immune development has long been observed in the field of
developmental immunotoxicology (Dietert, 2011). More recently,
age-dependent changes in innate immunity have also been linked
with age-specific windows of susceptibility to particular infections
(Kollmann et al., 2012). This suggests that specific environmental
cues during defined periods might also have specific consequences
for particular vaccine responses.
Infection
Postnatal exposure to microbes, be they infectious pathogens or
beneficial colonizers, has been documented to have lasting impact
on subsequent vaccine responses. While neonatal administration
of BCG itself appears to have no clear effect on innate immune
response in infants (Djuardi et al., 2010), the response to neonatal
BCG appears reduced following exposure to other environmen-
tal mycobacteria (reviewed in Fine, 1995; Djuardi et al., 2011).
Furthermore, the allergo-protective effects of BCG are more evi-
dent in children from low-income countries than in children from
high-income countries, suggesting that the effects of BCG on the
developing immune system might be influenced by other environ-
mental factors (van den Biggelaar et al., 2009). On the contrary,
the response to Hib-tetanus vaccination is hypothesized to be
enhanced following exposure to cross-reactive “Hib-like” envi-
ronmental bacteria (Levine et al., 1997). Heterologous immunity
between microbes is known to influence several human pathogens
and vaccine responses, besides mycobacteria and Hib (reviewed
in Fine, 1995). However, whether these observations are due to
cross-reaction of specific antigens, or (also) due to non-antigen-
specific modulation of the innate immune system (i.e., trained
innate immune memory) has yet to be determined.
Polyparasitism in infants is known to affect immune function
and vaccine responses in a non-antigen-specific manner (Labeaud
et al., 2009; Djuardi et al., 2011; Dauby et al., 2012). For example,
schistosoma infected children in Gabon display lower response
to TLR stimulation compared to their uninfected counterparts
(van der Kleij et al., 2004). Furthermore, intestinal helminths
reduce responses to BCG vaccination via the immunosuppres-
sive cytokine TGF-β (Elias et al., 2008). Filarial infections lead
to lower vaccine responses to tetanus toxoid (Cooper et al., 1998;
Nookala et al., 2004), and helminth-infected children mount lower
responses to influenza but higher responses to tetanus vaccination
(van Riet et al., 2007a,b). This indicates that helminth infections
may have a profound effect on particularly those vaccines that
need strong innate Th1-support to generate protective cellular or
humoral immune responses (Djuardi et al., 2011).
Malaria also impacts innate immune responses. Expression of
TLR2 is higher, and responses to its ligand, Pam3Cys, are enhanced
in P. falciparum-infected Ghanaian children compared to their
uninfected counterparts (Hartgers et al., 2008). The impact of
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malaria on innate immune status however is strongly influenced
by host genetics (Arama et al., 2011). For example, studies per-
formed in a rural area of Mali have shown strikingly different
susceptibility to P. falciparum infection between two different eth-
nic groups, the Fulani and the Dogon. These populations live
under similar social, cultural, and geographic conditions and are
exposed to identical malaria pressure (Arama et al., 2011). TLR4,
TLR7, and TLR9 responses were found to be strongly inhibited
by P. falciparum infection in Dogon children, while no such TLR
inhibition was observed in the Fulani children. Strikingly, the TLR-
induced IFN-γ release was completely abolished in the infected
Dogon children, while no difference was seen within infected and
non-infected Fulani (Arama et al., 2011). Given that Fulani chil-
dren show fewer clinical symptoms of malaria, and that parasites
are less frequently detected in their blood, and that they exhibit
higher titers of P. falciparum-specific IgG and IgM antibodies sug-
gests that genetic differences lead to important immunological
differences in anti-malarial innate immunity (Arama et al., 2011).
Furthermore, several reports document that children with acute
malaria show reduced responsiveness to many vaccines, including
tetanus toxoid, meningococcal polysaccharide, Hib conjugate, and
whole-cell vaccine of typhoid fever (reviewed in Hartgers et al.,
2008). Together, this argues that in the case of malaria variation in
host-pathogen interactions impact innate immunity and result in
different outcomes for vaccine responsiveness.
Vaccination
Developmental innate immune trajectories are possibly not only
influenced by infections, but also by other vaccines (and adju-
vants). There is increasing evidence suggesting that vaccines have
non-specific effects on overall morbidity and mortality (Aaby
et al., 2012); these effects may be mediated via non-antigen-
specific changes in innate immunity (Netea et al., 2011). The
findings of non-specific effects of vaccines are more pronounced
in girls than in boys (Aaby et al., 2012). Sex-based differences
in vaccine responses have long been noted (reviewed in Cook,
2008), and influence the clinical efficacy of influenza, hepatitis
A, hepatitis B, pneumococcal polysaccharide, and diphtheria vac-
cines as well as adverse reactions following rubella, measles, and
yellow fever vaccines. The mechanisms leading to these differ-
ences are still unknown but apparently not entirely related to
gonadal sex hormones (as differences are seen in pre-pubertal and
post-menopausal subjects not on hormone replacement therapy)
and not restricted to female sex (males had greater serological
response for pneumococcal, diphtheria, yellow fever, Venezuelan
equine encephalitis, and in some studies with rabies vaccine). It is
thus likely that variation in innate response to adjuvants may be
impacted by other vaccines as well as by the sex of the recipient.
Nutrition and microbiome
Nutrition directly impacts early life immune function (LeBouder
et al., 2006; Taylor et al., 2006), including innate immunity (affect-
ing nearly 1/3 of all variables; Belderbos et al., 2011). The best-
studied examples relate to the role of breast vs. bottle-feeding
(reviewed in Djuardi et al., 2011). The introduction of normal flora
to a newborn occurs mainly during delivery, with different modes
of delivery profoundly and lastingly affecting the composition of
microbiota (Huurre et al., 2008; Dominguez-Bello et al., 2010).
The microbial diversity increases with age and is influenced by
life events such as breast feeding, introduction of solid food, and
antibiotic administration (Penders, 2006), as well as other less well
defined differences in environmental exposures (Alm et al., 2002).
Differences in fecal microbial communities between western Euro-
pean children and rural African children have been documented
(De Filippo et al., 2010). Innate immune development in the young
is clearly modulated by changes in the composition of the micro-
biome (Figueiredo et al., 2009; Biagi et al., 2010; Renz et al., 2012).
However, if and how variation in microbiome affects response to
vaccination early in life has not been scrutinized in sufficient detail
to draw conclusions.
PERSPECTIVE
In this review I highlighted the existing examples of population-
based differences in vaccine efficacy and immune response, and
emphasized the centrally important role of adjuvant-induced
innate immune responses to vaccine mediated protection. I also
reviewed the published record documenting differences in innate
immune ontogeny between populations and analyzed the role
variation in host genetics and/or environmental exposures play
in affecting innate immune ontogeny and vaccine response. It is
currently impossible to draw on sufficient evidence to unequiv-
ocally assess the underlying hypothesis that differences between
populations of the innate immune response to adjuvants leads to
variation in vaccine efficacy. But variation in adjuvant responses
as a relevant mechanism leading to global variation in vaccine effi-
cacy is at least biologically plausible (Hill, 1965), and thus worthy
of scrutiny as it might indicate possible remedies to address the
striking disparity of vaccine effectiveness for children around the
world (Levine and Robins-Browne, 2009).
Following Dr. Alan Lucas’ efforts in identifying specific nutri-
tional defects and their impact on survival early in life, one could
postulate that “when such uncertainty exists about the reasons why
(vaccine responses) differ in subjects living in different parts of the
world, …, it is reasonable to challenge whether the right questions
have been asked. To throw more light on this uncertainty, it is instruc-
tive to examine how other fields of health intervention have generally
evolved. Usually this has been a three-stage process. In stage I, anec-
dotal observations raise the question, “is this worth pursing?” In stage
II, epidemiological and physiological research provide descriptive and
mechanistic data that raise testable hypotheses concerning the poten-
tial effect of intervention. Finally, in stage III, formal intervention
experiments test the efficacy and safety of clinical or public health
practice” (Lucas, 1998). Clearly, investigating the role of variation
in adjuvant-induced innate immunity for differences in outcomes
of vaccination between populations is currently at stage I (anec-
dotal evidence). The question to be asked then is: is this area of
investigation worth pursuing? The answer to this question must be
a resounding “yes,” voiced by∼three million infants who die every
year of vaccine preventable infections in mainly the resource-poor
regions of the world.
Adjuvants have been used for nearly a century and have helped
save millions of lives (Pulendran and Ahmed, 2011; Levy et al.,
2012). There is ample evidence to support the notion that the
adjuvants contained in our current vaccines are working in most
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populations most of the time; i.e., there is no reason to stop
using them. However, we do not know if the adjuvants we cur-
rently give are the best possible adjuvants for a given popula-
tion (or a given individual). We now have sufficient anecdotal
data in hand to present the testable (both on epidemiological
and mechanistic grounds) hypothesis that differences in adjuvant
responses between populations lead to differences in vaccine effi-
cacy. Required to ascend to this next level of investigation (Dr.
Lucas’ level II) is the financial commitment of vaccine devel-
opers and funders to support studies of sufficient power con-
trasting well-controlled cohorts around the world (Blimkie et al.,
2011). The implications of variation in adjuvant innate immune
response between different populations are enormous, compelling
all involved in vaccination of children to make every effort to find
the answers (Dockrell et al., 2012).
Despite the impressive success of the global, regional, and
national vaccine programs, immunization delivery will need to
become even more efficient, safer, and economical to provide pro-
tection to the ∼three million infants around the world dying
every year from vaccine preventable infections (Levine, 2011).
Ideally all vaccines should elicit long-term protection following
needle-free administration of just a single dose and without need
for a cold-chain. To accomplish this, effective adjuvants will be
required (Levine, 2011). Unfortunately, we know the least about
adjuvant responses in those that currently still suffer the most
from infections – children in resource-poor regions of the world.
As Dr. Gregory Poland, one of the pioneers examining the mole-
cular mechanisms responsible for variation in vaccine responses
states: The question that vaccinologists in the twenty-first cen-
tury must ask is “why immune responses to biologics and vaccines
vary among otherwise healthy recipients and what explains this
heterogeneity?” (Poland et al., 2011). The answer to this question
is particularly important for global vaccine programs, given the
number of subjects they aim to reach and the potentially serious
consequences should they fail to induce protection in particular
populations (Levine and Robins-Browne, 2009).
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